source
- NewLimit’s $435M megaround; Lilly’s busy dealmaking weekThe anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.BioPharma Dive · 1mo ago↗ source
- Regeneron doubles down on CytomX after other pharmas walked awayAfter losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator. Regeneron is doubling down on its partnership with the Bay Area bi…Endpoints · 1mo ago↗ source
- Mineralys makes money moves before looming hypertension approvalMineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator,…